What is Belsomra?
Belsomra (suvorexant) is a medication used for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. It is a selective orexin receptor antagonist that works by blocking the wake-promoting action of orexins in the brain, thereby promoting sleep [2].
How does Belsomra work?
Belsomra functions by inhibiting the binding of wake-promoting neuropeptides, orexin-A and orexin-B, to the OX1R and OX2R receptors [1][2]. The orexin system plays a significant role in regulating wakefulness, and by blocking these receptors, Belsomra reduces the drive to stay awake, facilitating sleep [2].
When is Belsomra expected to lose patent protection?
The earliest anticipated loss of market exclusivity for Belsomra is in 2026 [3]. This date is based on patent expiry information available from sources like DrugPatentWatch.com [3].
What are the different Belsomra dosage strengths?
Belsomra is available in several dosage strengths, typically ranging from 5 mg to 20 mg [4]. The appropriate dosage is determined by a healthcare provider based on individual patient needs and response.
Are there generic versions of Belsomra available?
As of late 2023, there are no generic versions of Belsomra available in the United States [5]. Generic availability is contingent upon patent expiry and the successful navigation of regulatory pathways by generic manufacturers.
What are the common side effects of Belsomra?
Common side effects reported with Belsomra include drowsiness, dizziness, fatigue, and nausea [1][4]. Patients are advised to avoid activities requiring mental alertness, such as driving, on the day after taking the medication due to potential residual daytime impairment [1].
What clinical data supports Belsomra's efficacy?
Clinical trials have demonstrated Belsomra's effectiveness in improving sleep onset latency and wake after sleep onset in adults with insomnia [2]. Studies also showed improvements in patient-reported sleep quality and duration [2].
Who manufactures Belsomra?
Belsomra is manufactured by Merck & Co., Inc. [1].